Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis

Abstract

Jolijn R van Leeuwen,1,* Tamara Popov,2,* Achim Obergfell,2 Ton J Rabelink,1 YK Onno Teng1 1Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden, the Netherlands; 2Vifor Pharma Ltd, Glattbrugg, Switzerland*These authors contributed equally to this workCorrespondence: YK Onno Teng, Department of Nephrology, Leiden University Medical Center (LUMC), P.O. Box 9600, 2300 RC, Leiden, the Netherlands, Tel [phone], Fax [phone], Email [email protected]

Keywords

• n/a